Analysts predict that Synlogic Inc (NASDAQ:SYBX) will announce ($0.55) earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have made estimates for Synlogic’s earnings, with estimates ranging from ($0.66) to ($0.44). Synlogic posted earnings per share of ($0.59) in the same quarter last year, which would indicate a positive year-over-year growth rate of 6.8%. The firm is expected to announce its next earnings report on Wednesday, August 14th.

On average, analysts expect that Synlogic will report full year earnings of ($2.28) per share for the current fiscal year, with EPS estimates ranging from ($2.65) to ($1.93). For the next financial year, analysts forecast that the business will report earnings of ($2.50) per share, with EPS estimates ranging from ($2.93) to ($1.91). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Synlogic.

Synlogic (NASDAQ:SYBX) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.51) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.03. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.42 million. Synlogic had a negative return on equity of 38.93% and a negative net margin of 2,005.43%.

Several equities analysts have commented on SYBX shares. Zacks Investment Research downgraded Synlogic from a “buy” rating to a “hold” rating in a research report on Tuesday, May 14th. Jefferies Financial Group started coverage on Synlogic in a research note on Tuesday, April 30th. They set a “buy” rating and a $18.00 price objective for the company. Piper Jaffray Companies upped their price objective on Synlogic from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday. Chardan Capital restated a “buy” rating and set a $20.00 price objective on shares of Synlogic in a research note on Tuesday, March 12th. Finally, Wedbush restated an “outperform” rating and set a $20.00 price objective on shares of Synlogic in a research note on Wednesday. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $18.68.

Institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc purchased a new stake in Synlogic in the third quarter valued at about $33,000. Bank of Montreal Can raised its stake in Synlogic by 5,743.1% in the first quarter. Bank of Montreal Can now owns 12,738 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 12,520 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Synlogic in the first quarter valued at about $114,000. Rhumbline Advisers raised its stake in Synlogic by 45.7% in the fourth quarter. Rhumbline Advisers now owns 21,753 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 6,820 shares during the last quarter. Finally, State of Wisconsin Investment Board raised its stake in Synlogic by 29.8% in the first quarter. State of Wisconsin Investment Board now owns 20,900 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 4,800 shares during the last quarter. Institutional investors own 81.89% of the company’s stock.

Shares of NASDAQ SYBX traded down $0.05 during trading hours on Friday, hitting $7.72. 230,683 shares of the company traded hands, compared to its average volume of 92,676. The company has a market cap of $197.28 million, a P/E ratio of -3.80 and a beta of 2.31. The company has a debt-to-equity ratio of 0.20, a quick ratio of 11.53 and a current ratio of 11.53. Synlogic has a 12 month low of $5.75 and a 12 month high of $14.59.

About Synlogic

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

See Also: What is Depreciation?

Get a free copy of the Zacks research report on Synlogic (SYBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.